Musculoskeletal Imaging

What Is the Best Imaging for Pulmonary Metastasis Surveillance in Musculoskeletal Tumors?

·
What Is the Best Imaging for Pulmonary Metastasis Surveillance in Musculoskeletal Tumors?

An oncologist is in clinic for a follow-up with a 24-year-old patient, two years post-resection and chemotherapy for a femoral osteosarcoma. The patient is doing well, is asymptomatic, and has no signs of local recurrence. Today’s visit is for routine surveillance, and the key clinical question is how to best screen for the most common site of distant metastasis: the lungs. The goal is to detect any potential spread early while minimizing unnecessary radiation and cost over the patient’s lifetime of surveillance. For this specific scenario—surveillance for pulmonary metastasis in a patient with a history of a malignant musculoskeletal tumor and no suspected recurrence—the American College of Radiology (ACR) rates CT chest without IV contrast as Usually Appropriate.

## Who Fits This Clinical Scenario for Musculoskeletal Tumor Surveillance?

This guidance applies to a specific patient population: individuals with a history of a treated malignant or aggressive primary musculoskeletal tumor who are undergoing routine, scheduled surveillance. The classic examples include high-grade sarcomas like osteosarcoma, Ewing sarcoma, and various soft tissue sarcomas, which have a known propensity for hematogenous spread to the lungs.

Inclusion criteria for this workflow:

  • A confirmed history of a malignant or aggressive primary musculoskeletal tumor that has been treated with curative intent.
  • The patient is asymptomatic, with no new cough, shortness of breath, hemoptysis, or chest pain.
  • There is no clinical suspicion or known evidence of local or distant tumor recurrence.
  • The imaging is being performed as part of a planned surveillance protocol.

Exclusion criteria (patients who fit a different workflow):

  • Initial Staging: Patients who have just been diagnosed and have not yet completed primary treatment require initial staging, which is a distinct clinical scenario with different imaging considerations.
  • Suspected Local Recurrence: Patients presenting with new pain, swelling, or a palpable mass at the site of the original tumor require dedicated imaging of the primary site, which falls under the surveillance for local recurrence scenarios.
  • Suspected Systemic Recurrence: Patients with symptoms concerning for metastatic disease (e.g., constitutional symptoms, new bone pain, or respiratory symptoms) may require a more comprehensive evaluation, potentially with different imaging modalities.

## What Are You Looking For During Pulmonary Metastasis Surveillance?

The primary goal of surveillance imaging in this context is the early detection of pulmonary metastases. For most high-grade musculoskeletal sarcomas, the lungs are the most common site of distant spread. Detecting these metastases when they are few in number (oligometastatic) and small in size can open the door to potentially curative treatments like metastasectomy or stereotactic body radiation therapy (SBRT).

The main diagnostic consideration is, therefore, pulmonary metastatic disease. Sarcoma metastases typically appear as multiple, bilateral, well-circumscribed, solid nodules, often with a peripheral or subpleural distribution. They tend to be spherical due to their hematogenous origin.

However, not every nodule found on a surveillance CT is a metastasis. The differential diagnosis includes several benign possibilities that the radiologist and clinician must consider:

  • Benign Granulomas: Often seen in endemic areas for fungal infections (like histoplasmosis or coccidioidomycosis), these are a very common cause of small, stable, or calcified lung nodules.
  • Intrapulmonary Lymph Nodes: These are normal structures that can appear as small, solid, well-defined nodules, typically in a subpleural location.
  • Post-Treatment Changes: While less common from primary extremity tumor treatment, certain chemotherapeutic agents can cause lung injury, and prior thoracic radiation would cause obvious changes.
  • New Primary Lung Cancer: This is a less frequent consideration in the typically younger sarcoma population but becomes more relevant in older patients or those with a significant smoking history.

The surveillance strategy is designed to identify new or growing nodules that are suspicious for metastasis against this background of other potential findings.

## Why Is CT Chest Without IV Contrast Usually Appropriate for Surveillance?

The ACR designates CT chest without IV contrast as Usually Appropriate because it provides the ideal balance of high diagnostic sensitivity for the target pathology while minimizing risks and costs for a test that will be repeated over many years.

The rationale is rooted in physics and pathology. The inherent high contrast between the air-filled lung parenchyma and solid soft-tissue-density metastatic nodules makes intravenous contrast media unnecessary for their detection. A non-contrast CT is exceptionally sensitive for identifying even very small nodules (a few millimeters in size), which is the primary task of surveillance.

Let’s compare this to the alternatives rated by the ACR for this specific scenario:

  • Radiography chest is rated Usually not appropriate. While it involves a very low radiation dose (☢ <0.1 mSv), its sensitivity for detecting small pulmonary nodules is poor. A chest radiograph can easily miss nodules smaller than 1 cm, potentially delaying the diagnosis of treatable metastatic disease and defeating the purpose of surveillance.
  • CT chest with IV contrast is also rated Usually not appropriate. Adding IV contrast does not improve the detection of parenchymal lung nodules. It does, however, add potential risks (allergic reaction, contrast-induced nephropathy), increase the cost of the exam, and slightly increase scan time. It provides no additional diagnostic value for this specific clinical question.
  • FDG-PET/CT whole body is rated May be appropriate. While it can detect metabolically active disease throughout the body, it is not the first-line tool for routine pulmonary surveillance. It involves a significantly higher radiation dose (☢☢☢☢ 10-30 mSv) and is less sensitive for very small (<8-10 mm) or non-FDG-avid nodules. Its role is typically reserved for situations where there is a higher suspicion of recurrence, indeterminate findings on a standard CT, or for tumor types known to be better characterized by metabolic activity.

Given that these patients undergo repeated scans, minimizing cumulative radiation exposure is a critical consideration. Many institutions employ low-dose CT protocols for this indication, further optimizing the risk-benefit ratio. The adult radiation level for a standard non-contrast chest CT is ☢☢☢ (1-10 mSv), and pediatric protocols must be carefully managed (☢☢☢☢ 3-10 mSv).

Once you’ve decided on CT chest without IV contrast, our protocol guide covers the technique, contrast, and reading principles: CT Chest Without Contrast.

## After the Scan: Navigating the Downstream Workflow for Musculoskeletal Tumor Surveillance

The results of the surveillance CT will dictate the next steps in management, which often involve a multidisciplinary discussion.

  • Negative Result: If the CT is negative for any new or suspicious nodules, the patient continues with their scheduled surveillance protocol. The frequency of imaging depends on the tumor type, grade, and time since initial treatment, with intervals typically lengthening over time.
  • Positive Result (New/Growing Nodules): If the scan reveals one or more new or unequivocally growing nodules suspicious for metastases, the next step is typically a consultation within a multidisciplinary sarcoma tumor board. The discussion will involve the oncologist, surgeon, and radiologist to determine the best course of action. This may include:
  • Surgical resection (metastasectomy) if the disease is limited.
  • SBRT for non-surgical candidates or specific nodule locations.
  • A change in systemic therapy.
  • Biopsy if the diagnosis is uncertain.
  • Indeterminate Result (Small, Stable, or Atypical Nodules): This is a common and challenging scenario. If one or more small, non-specific nodules are found, management depends on the degree of suspicion.
  • For very low-suspicion nodules (e.g., tiny, stable, or calcified), continued observation is standard.
  • For nodules of intermediate concern, a short-interval follow-up CT (e.g., in 3 months) is often recommended to assess for growth, which is a key indicator of malignancy.
  • In complex cases, an FDG-PET/CT (May be appropriate) may be considered to assess the metabolic activity of the nodules and look for other sites of disease.

## Pitfalls to Avoid (and When to Get Help)

Several common pitfalls can occur in this specific surveillance workflow. Awareness of these can help ensure optimal patient care.

  • Using Chest X-Ray for Surveillance: Relying on chest radiography due to its low radiation dose is a significant pitfall, as its low sensitivity can lead to false negatives and a delayed diagnosis.
  • Routinely Ordering IV Contrast: Adding IV contrast to a routine surveillance chest CT for lung nodule detection is unnecessary, adds risk and cost, and should be avoided unless there is a specific co-existing indication (e.g., suspected hilar/mediastinal involvement or vascular issues).
  • Ignoring Cumulative Radiation Dose: Failing to use low-dose protocols, especially in younger patients who will undergo many years of surveillance, is a missed opportunity to minimize long-term risk.
  • Overreacting to Indeterminate Nodules: Not all new nodules are metastases. A structured approach with short-term follow-up for indeterminate findings can prevent unnecessary anxiety and invasive procedures for benign lesions.

If a surveillance scan shows rapidly progressing or numerous nodules, or if the patient develops new symptoms, an urgent escalation to the treating oncologist or sarcoma tumor board is warranted.

## Related ACR Topics and Tools

This article focuses on a single clinical scenario. For a comprehensive overview of imaging for all related presentations, and for tools to help you order the right study, see the resources below.

Frequently Asked Questions

Why not just use a chest X-ray to reduce radiation exposure during surveillance?

A chest X-ray is rated ‘Usually not appropriate’ by the ACR for this purpose because it has poor sensitivity for small pulmonary nodules. It can easily miss metastases when they are small and most treatable, defeating the primary goal of surveillance. A low-dose non-contrast CT is the standard because it provides high sensitivity at an optimized radiation dose.

If a single new lung nodule is found, is it always a metastasis?

No. A single new lung nodule can be a metastasis, but it could also be a benign finding like a granuloma or a new primary lung cancer, especially in older patients. The management often involves a short-interval follow-up CT to assess for growth, which strongly suggests malignancy. A biopsy may be necessary if the diagnosis remains uncertain.

When is an FDG-PET/CT scan appropriate for musculoskeletal tumor surveillance?

FDG-PET/CT is rated ‘May be appropriate’ and is not the first-line tool for routine pulmonary surveillance. It is typically reserved for specific situations, such as evaluating indeterminate nodules seen on CT, when there is a clinical suspicion of recurrence elsewhere in the body, or for staging in tumor types known to be highly FDG-avid.

Do I need to order IV contrast if I’m worried about mediastinal or hilar lymph node involvement?

For routine surveillance of an asymptomatic patient, IV contrast is not necessary. Non-contrast CT can still visualize lymph node size. If there is a specific finding on the non-contrast scan or a clinical concern for mediastinal disease, a subsequent contrast-enhanced CT or PET/CT might be warranted, but it should not be the default surveillance study.

How does the surveillance protocol change for pediatric patients?

The principle of using non-contrast CT remains the same, but minimizing radiation dose is even more critical. All pediatric CT scans should be performed using established low-dose protocols (‘As Low As Reasonably Achievable’ – ALARA principle). The ACR notes a pediatric radiation level of ☢☢☢☢ (3-10 mSv) for this exam, emphasizing the need for careful protocol optimization by the radiology department.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026